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IN THE last decade, many reports have
attested to the clinical benefits ofimmuno-
therapy in the treatment of malignant
diseases. Extensive reviews ofthese pub-
lications have recently appeared (Nathan-
son, 1974; Gutterman et al., 1974).
Although experimental evidence regarding
the mechanism of action of BCG and/or
inactivated tumour cells on animal im-
mune systems is abundant (Halpern et
al., 1959; Old et al., 1961; Mathe et al.,
1973) consistent data in humans are still
scanty.
The purpose of the present study was
to evaluate the effect ofsuch a therapeutic
programmne on the circulating mono-
nuclear cell population in patients in
complete remission from acute lympho-
cytic leukaemia (ALL). To this end,
we compared a group of patients on
long-term immunotherapy with a similar
group receiving standard maintenance
chemotherapy and with a group ofnormal
individuals.
Thirty-one patients with ALL cur-
rently in remission were studied. Twenty
of these were receiving immunotherapy
and 11 chemotherapy at the time they
were tested. Immunotherapy consisted
of fresh live BCG (Pasteur) administered
by scarification at intervals ranging from
once weekly to once monthly and irradi-
ated allogenic blast cells (108) administered
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intradermally (Mathe et al., 1969). Chemo-
therapy consisted of weekly methotrexate
and cyclophosphamide plus daily 6-mer-
captopurine.
A summary of the age and sex dis-
tribution, plus the duration of mainten-
ance treatment is presented in Table I.
Although the patients investigated were
drawn from various protocols, all such
regimes consisted of a phase of post-
induction chemotherapy followed by im-
munotherapy. Accordingly, the immuno-
therapy group had received a variable
period of post-remission chemotherapy
and then a period of immunotherapy
ranging, as seen on Table I, from 13
to 96 months. The patients in the chemo-
therapy group are those who have received
prophylactic central nervous system irra-
diation and who have not yet completed
the chemotherapy phase of the current
ALL protocol. The duration of their
maintenance therapy at the time of this
study ranged from 3 to 14 months. There
are no patients currently being followed
without maintenance immuno- or chemo-
therapy to provide a " no treatment"
group for comparison.
Total and differential white cell counts
were performed on all subjects. The
absolute number of each category of
cells/mm3 was calculated by multiplying
the percentages obtained in the following
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TABLE I. Groups Studied (ALL in Corplete Remission)
Chemotherapy
Immunotherapy
(post-chemotherapy)
Normals
Number of Age
patients Sex (mean+range)
11 OM 10 1 years
I F (5-31)
20 7 M 11 5 years
13 F (4-21)
9 4 M 30 years
5 F (20-50)
Duration of
maintenance treatment
(mean+range)
8 9 months
(3-14)
28 * 2 months
(13-96)
procedures by the absolute number of
mononuclear cells/mm3. Peripheral blood
was collected in citrate from each subject
and the mononuclear cells isolated and
purified by a previously described Ficoll
gradient procedure (Belpomme et al.,
1974). After at least three washings,
these cells were used in the tests described
below.
T lymphocytes were enumerated by
the E rosette test using sheep red blood
cells (SRBC). Rosettes were defined as
lymphocytes surrounded by at least three
SRBC. We performed this test in two
ways. In the first, or direct test, rosettes
resulting from the incubation of mono-
nuclear cells and SRBC alone were
counted (ERFC) (Belpomme et al.,
1974). In the second, or AB serum test,
AB human serum, previously decomple-
mented and absorbed with SRBC, was
added to the incubation mixture
(EABRFC). We, as others, have pre-
viously shown that this latter procedure
gives a higher number of rosettes than
the former (Bentwich and Kunkel, 1973;
Belpomme,personal communication). This
phenomenon mayberelatedtothedetection
ofthe total number of T cells by the sen-
sitized test, while the direct test may
define a sub-population ofthe group.
Enumeration of B lymphocytes was
performed by determination of membrane
immunoglobulin (mlg) using a direct
immunofluorescent test with a polyvalent
fluorescent isothiocyanate-conjugated
sheep anti-human immunoglobulin serum.
Details of this method have been pre-
viously described (Belpomme et al., 1974).
Monocytes were enumerated by per-
oxidase staining as suggested by a recent
WHO Workshop (Aiuti et al., 1974). One
thousand mononuclear cells were counted
for peroxidase positivity on each slide.
After establishing the absolute number
of each of the three foregoing groups
(EABRFC, mlg+ cells, peroxidase+ cells)
we calculated the number of so-called
" null " cells by subtraction: " Null "
cells = mononuclear cells - (EABRFC +
mIg+ cells + peroxidase+ cells). Statis-
tical analyses were performed by
Student's t test.
Table II presents a summary of our
results expressed in mean values, with
ranges given in each instance. Since
similar degrees of variation were seen
in all groups, the use of mean values
was considered justified.
The patients on chemotherapy had a
significant reduction in number of mono-
nuclear cells and of total number of
EABRFC in comparison with both the
immunotherapy and normal groups. No
such difference was noted in either the
total number of mlg+ or peroxidase+
cells. When " null " cells were calculated
there was no difference from normals,
but there were far fewer (P -0-001) in
this group than in the patients receiving
immunotherapy.
The immunotherapy group demon-
strated no significant difference from
the normal group except in the calculated
"null cells ". There was a much larger
mean number of-such cells in the immuno-
therapy group than in the normal
(P- 001).
In our study the percentages and total
numbers of EABRFC, mIg+ and per-
oxidase+ cells in normal individuals were
in the range previously published (Wybran
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Normal
TABLE II.-Summary of Results
Mononuclear*
cells EABRFC* mlg*
(667-2500) (44-1180) (67-1400)
1470 696 455
(1200-5360) (456-2081) (125-1126)
2714 1173 467
(1100-3900) (517-1863) (110-720)
2356 1299 381
Comparisons
Chemotherapy/immunotherapy
Normal/chemotherapy
Normal/immunotherapy
P<0 001 P=0 01 N.S.
P=0-02 P=0 01 N.S.
N.S. N.S. N.S.
N.S. P<0*001
N.S. X.S.
N.S. Ps<001
* Number/mm3 (range) and mean.
t As % mononuclear cells.
and Fudenberg, 1974). The calculated
" null " cells were also in agreement with
available data. Our control group was
composed of subjects in an older age
group than our patient groups because
of the logistic difficulty of obtaining
normal pediatric subjects. Several recent
reports give conflicting results on the
influence of age on the distribution of
B and T cells. For example, one study
(Weksler and Hutteroth, 1974) found no
change in absolute number of peripheral
lymphocytes or B and T cells with in-
creasing age, while another (Carosella,
Mochanko and Brown, 1974) demonstrated
a decreased percentage ofT cells occurring
somewhere between 46 and 60 years of
age. Since our control group had a
mean age (30 years) considerably younger
than this we believe that age difference
does not represent a significant problem
in analysis of our results.
A striking finding of our study is
the significant elevation in the absolute
number and percentage of " null " cells
in the immunotherapy group as compared
with both the chemotherapy and normal
groups. Although the nature of these
cells is still unknown, several hypotheses
concerning their increase in this situation
can be entertained.
(1) These cells may represent abnormal
elements persisting even during apparently
complete remission of acute lymphocytic
leukaemia. The continued perfect clinical
and cytological condition of these patients
does not favour this hypothesis.
(2) They may be stem cells circulating
in the peripheral blood. Although it
has been demonstrated that BCG can
increase haematopoietic stem cells in
mouse bone marrow (Pouillart, personal
communication) human data are lacking.
(3) They may be " K " cells. It has
been shown that there is increased " K "
cell activity in patients on BCG therapy
for acute lymphocytic leukaemia in com-
parison to patients receiving no treat-
ment (MacLennan, 1975). This hypo-
thesis seems plausible since it has recently
been suggested that " K " cells may be
" null " cells (Greenberg et al., 1973).
(4) They may represent T or B lym-
phocytes or monocytes which have lost
any detectable markers, a change possibly
induced by immunotherapy.
(5) A final possibility is that there
may not be a true increase in these cells,
but rather a redistribution between the
peripheral blood and the various reticulo-
endothelial organs.
Further studies are in progress in
our laboratory to confirm these pre-
liminary results and to elucidate the nature
of these intriguing cells.
We gratefully acknowledge the tech-
nical cooperation of Daniele Grandjon
and the statistical assistance of G. Hauss.
Peroxi-
dase*
(0-728)
344
(0-807)
198
(60-936)
396
" Null "
(0-460)
104
(174-1824)
883
(0-1209)
304
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